Disc Medicine
Disc Medicine is a clinical-stage biopharmaceutical company developing small-molecule and biologic therapies for rare hematologic diseases, including erythropoietic protoporphyria, polycythemia vera, and sickle cell disease, targeting specialty hematology prescribers and rare disease patient populations.
- Company typePublic
- Founded2022
- HeadquartersWatertown, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Disc Medicine does
Disc Medicine is a clinical-stage biopharmaceutical company developing therapies for hematologic diseases and rare blood disorders. Founded in 2017 and headquartered in Watertown, Massachusetts, the company is publicly traded on NASDAQ under the ticker IRON after a 2022 reverse merger with Gemini Therapeutics. The company applies two core biological mechanisms across its pipeline: heme biosynthesis modulation via the GlyT1 inhibitor bitopertin, originally licensed from Roche, and hepcidin pathway modulation via anti-hemojuvelin antibody DISC-0974 (AbbVie/Mabwell-licensed) and anti-TMPRSS6 siRNA DISC-3405 (Kyowa Kirin-licensed). Lead candidate bitopertin is in Phase 3 for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Phase 2 for Diamond-Blackfan anemia (DBA). DISC-0974 is in Phase 1/2 development for anemia in myelofibrosis, inflammatory bowel disease, and chronic kidney disease. DISC-3405 is in Phase 2 for polycythemia vera and Phase 1 for sickle cell disease. The company has no commercialized products, no recurring revenue, and is funded entirely through equity capital, with approximately $730M in cash and equivalents following an October 2025 $250M public offering, providing runway into 2029.
The company's business model is conventional clinical-stage biopharma: it advances in-licensed or internally-discovered therapeutic candidates through clinical trials toward regulatory approval, with the intent of either commercializing independently via a specialty sales force in the rare disease space, or partnering ex-U.S. rights to a larger pharmaceutical company. Disc Medicine was actively building pre-commercial capabilities, including medical science liaison deployment and field force expansion, in advance of a planned bitopertin launch in EPP. In February 2026, the FDA issued a Complete Response Letter for the bitopertin NDA, leading the company to announce a 20% workforce reduction, pausing of certain pipeline programs (DISC-3405 in CKD anemia, narrowing of DISC-0974), and securities litigation. A June 2026 Type A meeting with the FDA aligned on a path to resubmit the bitopertin NDA using existing Phase 3 APOLLO data, restoring a clearer regulatory pathway. Target customer segments are highly concentrated specialty hematology prescribers, genetic disease specialists, and rare disease patients identified through specialized treatment centers in the U.S., with potential ex-U.S. commercialization via partnership.
Disc Medicine firmographics
Firmographics- Name
- Disc Medicine
- Legal name
- Disc Medicine, Inc.
- Website
- https://discmedicine.com
- Company type
- Public
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Disc Medicine is a clinical-stage biopharmaceutical company developing small-molecule and biologic therapies for rare hematologic diseases, including erythropoietic protoporphyria, polycythemia vera, and sickle cell disease, targeting specialty hematology prescribers and rare disease patient populations.
- Ownership category
- akta.pro rank
Disc Medicine industry classification
Industry- Product category
- Rare Hematology Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)
- akta.pro secondary industries
- Rare Oncology & Hematologic Malignancy Therapies (HLAIAIAC), Rare Cardiovascular & Vascular Disorder Therapies (HLAIAIAH), Rare Endocrine & Growth Disorder Therapies (HLAIAIAJ)
Keywords
Where Disc Medicine is headquartered
LocationHeadquarters
- HQ city
- Watertown
- HQ country
- United States
- HQ region
- North America
Offices4 records
Markets served
Disc Medicine business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Others
Revenue model
- Pre-Revenue / Clinical Stage: Disc Medicine is pre-revenue. The company reported a loss of $241.60m with no revenue as of mid-2026. Net loss for FY2025 was $212.2M (vs. $109.4M in 2024) and Q1 2026 net loss was $63.5M (vs. $34.1M in Q1 2025). Future revenue expected from drug commercialization if/when approved.
- Future Drug Commercialization (Planned): Intends to use $250M October 2025 offering proceeds to support potential commercialization of its drug for hematologic diseases. Expected future revenue model would be standard biopharma drug sales / specialty pharma commercialization targeting rare disease populations.
- Bitopertin In-Licensing from Roche: Bitopertin was in-licensed from Roche in May 2021. Disc obtained global rights to develop and commercialize bitopertin, with Roche receiving milestone and royalty entitlements (financial structure not publicly disclosed in detail).
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | — | Not applicable — pre-revenue, clinical-stage company with no approved products. |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels8 records
Disc Medicine product offering
Product offeringCore offering
Disc Medicine is a clinical-stage biopharmaceutical company developing investigational therapies for hematologic diseases and rare blood disorders. The company's pipeline targets two core biological processes: heme biosynthesis modulation and hepcidin pathway modulation (both suppression and induction). Lead assets include bitopertin (oral GlyT1 inhibitor for EPP/XLP), DISC-0974 (anti-HJV antibody for anemia of inflammation), DISC-3405 (anti-TMPRSS6 antibody for iron overload disorders), and DISC-0998 (preclinical anti-HJV). The company is pre-revenue with no approved products on the market.
Product overview
Disc Medicine is a clinical-stage biopharmaceutical company developing therapeutics for hematologic diseases. No detailed product/module breakdown is supported by properly attributed source data.
Differentiator
Problem solved
Functional benefit
Products and services
- Bitopertin Oral selective inhibitor of glycine transporter 1 (GlyT1) that limits glycine uptake into developing red blood cells, regulating downstream heme biosynthesis and reducing toxic protoporphyrin IX (PPIX) accumulation. In-licensed from Roche and being developed for EPP, XLP, and DBA. Currently in Phase 3 APOLLO trial (183 participants across US, Canada, Europe, Australia), with topline data expected Q4 2026 and potential FDA decision anticipated by mid-2027 following the February 2026 Complete Response Letter.
- DISC-0974 Anti-hemojuvelin (HJV) monoclonal antibody that binds HJV to suppress hepcidin expression, enhancing iron availability for erythropoiesis to treat anemia of inflammation. In-licensed from AbbVie. Phase 2 RALLY-MF trial reported 70% overall response rate with 54-67% major response rates across evaluable cohorts in myelofibrosis patients.
- DISC-3405 Recombinant humanized monoclonal antibody targeting TMPRSS6 (Matriptase-2) to induce endogenous hepcidin expression, reducing iron levels for diseases enabled by iron availability. Mechanism validated by human genetics (IRIDA patients with TMPRSS6 mutations). In-licensed from Mabwell. Holds FDA Fast Track Designation for polycythemia vera (PV).
- DISC-0998
- Bitopertin Expanded Access Program (EAP) Expanded Access Program providing investigational bitopertin to eligible EPP/XLP patients who lack satisfactory therapeutic alternatives. Listed on ClinicalTrials.gov (NCT07603401) and accessible via [email protected]. Functions as the current pre-approval access pathway for the lead asset.
Quantifiable outcome
- 55-64% major response rates in myelofibrosis patients across subgroups in DISC-0974 RALLY-MF Phase 2 trial
- +3 more outcomes
Companies that use Disc Medicine
Customer profileNamed customers2 records
Ideal customer profiles2 records
Disc Medicine technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Disc Medicine partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and flagship.
- Gemini TherapeuticscoreGemini Therapeutics announced plans to merge with Disc Medicine in August 2022, as part of Gemini's strategic restructuring efforts. The merger brought together Gemini's ocular/age-related macular degeneration program with Disc's hematology pipeline; Georges Gemayel (former Executive Chair of Gemini Therapeutics) now serves on Disc Medicine's Board of Directors.
- RocheflagshipBitopertin (GlyT1 inhibitor) was in-licensed from Roche in May 2021, with Disc obtaining global rights to develop and commercialize the asset for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) and other conditions associated with abnormal erythropoiesis. Bitopertin was previously studied in over 4,000 participants across other indications, providing extensive safety characterization.
- AbbVieflagshipDISC-0974 (anti-hemojuvelin monoclonal antibody for anemia of inflammation) and DISC-0998 (extended half-life anti-HJV antibody) were in-licensed from AbbVie. Disc has advanced DISC-0974 into multiple Phase 1b/2 and Phase 2 studies in myelofibrosis, inflammatory bowel disease, and chronic kidney disease.
- Mabwell TherapeuticsflagshipDISC-3405 (anti-TMPRSS6 monoclonal antibody, formerly MWTX-003) was in-licensed from Mabwell Therapeutics. Mabwell (Shanghai) Bioscience Co., Ltd. holds international licensing partnership with Disc worth up to US$412.5 million. Phase 1 healthy volunteer study completed; Phase 2 PV (FDA Fast Track) and Phase 1b SCD studies initiated.
- National Institutes of Health (NIH)coreInvestigator-initiated trial with NIH for bitopertin in Diamond Blackfan Anemia (DBA), a rare congenital bone marrow failure syndrome. This is a Phase 2 study leveraging the bitopertin mechanism for heme modulation in a second indication.
Scale indicators10 records
Recent moves6 records
Expansion highlights5 records
Disc Medicine competitors and assessment
Company assessmentMarket position
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Disc Medicine social profiles
Digital presenceDisc Medicine financial estimates
Financial estimateRevenue estimate
Valuation estimate
Disc Medicine leadership team
Management profileNumber of profiles
Profiles15 records
Disc Medicine funding detail
Funding detailFunding overview
Funding rounds10 records
Investors20 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Disc Medicine M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Disc Medicine
What does Disc Medicine do?
Disc Medicine is a clinical-stage biopharmaceutical company developing investigational therapies for hematologic diseases and rare blood disorders. The company's pipeline targets two core biological processes: heme biosynthesis modulation and hepcidin pathway modulation (both suppression and induction). Lead assets include bitopertin (oral GlyT1 inhibitor for EPP/XLP), DISC-0974 (anti-HJV antibody for anemia of inflammation), DISC-3405 (anti-TMPRSS6 antibody for iron overload disorders), and DISC-0998 (preclinical anti-HJV). The company is pre-revenue with no approved products on the market.
Is Disc Medicine a public or private company?
Disc Medicine is a public company. It is classified as public and is currently operating.
When was Disc Medicine founded?
Disc Medicine was founded in 2022. It employs 101 to 250 people.
Where is Disc Medicine based?
Disc Medicine is headquartered in Watertown, United States, in the North America region.
How does Disc Medicine make money?
Three revenue lines are on record. Pre-Revenue / Clinical Stage is the primary driver. The others are future Drug Commercialization (Planned) and bitopertin In-Licensing from Roche.
Does Disc Medicine have an API?
No public API is recorded for Disc Medicine.
What industry is Disc Medicine in?
Disc Medicine's product category is Rare Hematology Biopharmaceuticals. Its primary akta.pro industry code is HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO, with a secondary code of HLAIAIAC, Rare Oncology & Hematologic Malignancy Therapies. Its NAICS code is 325414 and its SIC code is 2834.